Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

J & J Unit Recalls Pain Patches Over Defect

By Pharmaceutical Processing | January 5, 2009

NEW YORK (AP) – Johnson & Johnson’s PriCara division has recalled two lots of the pain patch Duragesic, or fentanyl, because of tears in the products that could expose users directly to the product’s effective gel, causing an overdose. In February, the New Brunswick, N.J.-based company issued a similar recall, but on a larger scale for a less potent dosage of the drug. In a statement, the company said the latest manufacturing problems have been corrected. Duragesic, or fentanyl, is a potent opioid pain reliever and skin exposure directly to the gel within the patch can lead to respiratory problems and a fatal overdose. ALZA Corp., an affiliate of PriCara, manufactured the patches being recalled. The company said Duragesic 50 mcg/hr patches under the lot number 0817239 are being recalled. Anyone with that product should call 800-547-6446. Also, Sandoz Inc. 50 mcg/hr patches under the lot number 0816851 are being recalled. People with products containing that lot number should call 800-901-7236. PriCara urged anyone who comes in contact with fentanyl gel to thoroughly wash exposed skin with water only as anything else may only increase the medicine’s ability to go through the skin. Patches with cut edges should be carefully disposed of by flushing them down the toilet, without directly handling them. The latest problem is smaller than a February recall when all lots of 25 mcg/hr patches, a less potent dose, were recalled. Those products had similar defects and were also manufactured by ALZA. PriCara is a division of Ortho-McNeil-Janssen Pharmaceuticals Inc., a unit of consumer and health care products company Johnson & Johnson. The recall is being conducted in conjunction with the Food and Drug Administration. Other strengths including 12.5, 25, 75 and 100 mcg/hr are not affected, the company added.

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE